Pancreatic Cancer Research

ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Shibing Wang

Matched on ORCID iD 0000-0002-7772-220X; OpenAlex author ID A5102747518. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 7

  1. [Corrigendum] Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic canc… Last author DOI 10.3892/or.2025.9013↗
  2. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2322173↗
  3. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarci… Co-author DOI 10.1089/hum.2020.024↗
  4. Expression of Spindle and Kinetochore-related Complex Subunit 3 is Associate With the Progression and Prognosis of Hepatocellular Carcinoma and Pancreatic Aden… Last author DOI 10.21203/rs.3.rs-40794/v1↗
  5. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. Last author DOI 10.3892/or.2018.6817↗
  6. ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer. Co-author DOI 10.18632/oncotarget.21095↗
  7. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer. Last author DOI 10.3892/mmr.2017.6472↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wanyuan Chen · 3 shared papers, 2019–2026 · strength 0.53
  2. Weimin Fan · 2 shared papers, 2019–2026 · strength 0.42
  3. Xiangmin Tong · 1 shared paper, 2024 · strength 0.22
  4. Wei Wei · 1 shared paper, 2024 · strength 0.22
  5. Yigang Wang · 2 shared papers, 2017–2020 · strength 0.19
  6. You-Ni Zhang · 1 shared paper, 2020 · strength 0.13
  7. Hui‐Ju Wang · 1 shared paper, 2020 · strength 0.13
  8. Kuiwei Su · 1 shared paper, 2020 · strength 0.11
  9. Yinfang Wu · 1 shared paper, 2017 · strength 0.09
  10. Xiaodong Sun · 1 shared paper, 2017 · strength 0.09
  11. Ying‐Yu Ma · 1 shared paper, 2017 · strength 0.07
  12. Yun Ge · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.